Functional Validation of a Multispecific T-cell Engager in Acute Myeloid Leukemia Using Patient-Derived Samples
The development of multispecific T-cell engagers (TCEs) represents a promising strategy in hematologic malignancies, particularly in acute myeloid leukemia (AML). These molecules aim to redirect T-cell cytotoxicity toward leukemic blasts while sparing normal hematopoietic stem and progenitor cells. Despite encouraging preclinical concepts, demonstrating both efficacy and safety in translational models remains a major challenge prior to clinical entry.